| The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins LS Harrington, GM Findlay, A Gray, T Tolkacheva, S Wigfield, H Rebholz, ... Journal of Cell Biology 166 (2), 213-223, 2004 | 1395 | 2004 |
| Redox regulation of PI 3‐kinase signalling via inactivation of PTEN NR Leslie, D Bennett, YE Lindsay, H Stewart, A Gray, CP Downes The EMBO journal, 2003 | 728 | 2003 |
| PTEN function: how normal cells control it and tumour cells lose it NR Leslie, CP Downes Biochemical Journal 382 (1), 1-11, 2004 | 582 | 2004 |
| PTEN: The down side of PI 3-kinase signalling NR Leslie, CP Downes Cellular signalling 14 (4), 285-295, 2002 | 546 | 2002 |
| PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability A Silva, JA Yunes, BA Cardoso, LR Martins, PY Jotta, M Abecasis, ... The Journal of clinical investigation 118 (11), 3762-3774, 2008 | 503 | 2008 |
| GSK3 and its interactions with the PI3K/AKT/mTOR signalling network MA Hermida, JD Kumar, NR Leslie Advances in biological regulation 65, 5-15, 2017 | 472 | 2017 |
| Three-dimensional bioprinting of complex cell laden alginate hydrogel structures AG Tabriz, MA Hermida, NR Leslie, W Shu Biofabrication 7 (4), 045012, 2015 | 409 | 2015 |
| Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity J Cao, J Schulte, A Knight, NR Leslie, A Zagozdzon, R Bronson, ... The EMBO journal 28 (10), 1505-1517, 2009 | 405 | 2009 |
| Mechanisms of PTEN loss in cancer: It’s all about diversity V Álvarez-Garcia, Y Tawil, HM Wise, NR Leslie Seminars in cancer biology 59, 66-79, 2019 | 386 | 2019 |
| Understanding PTEN regulation: PIP2, polarity and protein stability NR Leslie, IH Batty, H Maccario, L Davidson, CP Downes Oncogene 27 (41), 5464-5476, 2008 | 297 | 2008 |
| 3D printing in suspension baths: keeping the promises of bioprinting afloat A McCormack, CB Highley, NR Leslie, FPW Melchels Trends in biotechnology 38 (6), 584-593, 2020 | 280 | 2020 |
| Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells SA Hawley, FA Ross, GJ Gowans, P Tibarewal, NR Leslie, DG Hardie Biochemical Journal 459 (2), 275-287, 2014 | 273 | 2014 |
| Prostate cancer, PI3K, PTEN and prognosis HM Wise, MA Hermida, NR Leslie Clinical science 131 (3), 197-210, 2017 | 234 | 2017 |
| Small molecule antagonists of the σ-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo BA Spruce, LA Campbell, N McTavish, MA Cooper, MVL Appleyard, ... Cancer research 64 (14), 4875-4886, 2004 | 229 | 2004 |
| PtdIns (3, 4, 5) P3-dependent and-independent roles for PTEN in the control of cell migration NR Leslie, X Yang, CP Downes, CJ Weijer Current Biology 17 (2), 115-125, 2007 | 219 | 2007 |
| PTEN is destabilized by phosphorylation on Thr366 H Maccario, NM Perera, L Davidson, CP Downes, NR Leslie Biochemical Journal 405 (3), 439-444, 2007 | 205 | 2007 |
| Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors LS Steelman, PM Navolanic, ML Sokolosky, JR Taylor, BD Lehmann, ... Oncogene 27 (29), 4086-4095, 2008 | 200 | 2008 |
| The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif SM Walker, NR Leslie, NM Perera, IH Batty, CP Downes Biochemical Journal 379 (2), 301-307, 2004 | 194 | 2004 |
| TPIP: a novel phosphoinositide 3-phosphatase SM Walker, CP Downes, NR Leslie Biochemical Journal 360 (2), 277-283, 2001 | 190 | 2001 |
| Non-genomic loss of PTEN function in cancer: not in my genes NR Leslie, M Foti Trends in pharmacological sciences 32 (3), 131-140, 2011 | 187 | 2011 |